Total Payments
$63,874
2024 Payments
$11,797
Companies
74
Transactions
715
Medicare Patients
10,461
Medicare Billing
$1.5M
Payment Breakdown by Category
Consulting$36,393 (57.0%)
Food & Beverage$16,511 (25.8%)
Travel$5,036 (7.9%)
Other$4,050 (6.3%)
Research$1,519 (2.4%)
Education$366.05 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,393 | 18 | 57.0% |
| Food and Beverage | $16,511 | 655 | 25.8% |
| Travel and Lodging | $5,036 | 26 | 7.9% |
| Honoraria | $4,050 | 4 | 6.3% |
| Unspecified | $1,519 | 1 | 2.4% |
| Education | $366.05 | 11 | 0.6% |
Payments by Type
General
$62,356
714 transactions
Research
$1,519
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $19,177 | 48 | $0 (2024) |
| Gilead Sciences, Inc. | $5,472 | 24 | $0 (2024) |
| Pharmacosmos Therapeutics Inc. | $4,163 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,573 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,369 | 55 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $3,316 | 17 | $0 (2024) |
| BeiGene USA, Inc. | $2,695 | 4 | $0 (2024) |
| Eisai Inc. | $2,340 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,115 | 81 | $0 (2024) |
| Kite Pharma, Inc. | $1,712 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,797 | 161 | BeiGene USA, Inc. ($2,676) |
| 2023 | $4,273 | 123 | Eli Lilly and Company ($1,519) |
| 2022 | $6,166 | 102 | Pharmacosmos Therapeutics Inc. ($4,142) |
| 2021 | $6,701 | 40 | Kite Pharma, Inc. ($1,712) |
| 2020 | $3,393 | 27 | Celgene Corporation ($1,800) |
| 2019 | $10,551 | 76 | Celgene Corporation ($8,456) |
| 2018 | $9,281 | 106 | Gilead Sciences, Inc. ($5,229) |
| 2017 | $11,712 | 80 | Celgene Corporation ($8,307) |
All Payment Transactions
715 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.96 | General |
| Category: Hematology | ||||||
| 12/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $26.88 | General |
| 12/12/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $28.45 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $125.23 | General |
| Category: Oncology | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/04/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $17.81 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $27.01 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Oncology | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: Oncology | ||||||
| 11/19/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Incyte Corporation | PEMAZYRE (Drug), JAKAFI, MONJUVI | Food and Beverage | Cash or cash equivalent | $20.20 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $22.22 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/05/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $28.53 | General |
| Category: Oncology | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $25.77 | General |
| Category: Oncology | ||||||
| 10/31/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $22.55 | General |
| Category: Hematology | ||||||
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $19.65 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $59.27 | General |
| Category: NONE | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | Eli Lilly and Company | $1,519 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 2,494 | 5,748 | $1.6M | $401,946 |
| 2022 | 11 | 2,329 | 5,184 | $1.2M | $372,077 |
| 2021 | 12 | 2,806 | 5,721 | $999,656 | $372,467 |
| 2020 | 12 | 2,832 | 6,021 | $1.1M | $354,784 |
Total Patients
10,461
Total Services
22,674
Medicare Billing
$1.5M
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 777 | 2,286 | $840,875 | $210,877 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 861 | 1,659 | $431,854 | $104,854 | 24.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 188 | 271 | $140,280 | $35,863 | 25.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 199 | 200 | $127,164 | $30,779 | 24.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 354 | 1,193 | $38,176 | $9,063 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $24,498 | $6,116 | 25.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 18 | 18 | $9,044 | $2,151 | 23.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 14 | 14 | $4,492 | $1,066 | 23.7% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 19 | 41 | $3,028 | $751.53 | 24.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 15 | $2,417 | $424.86 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 752 | 2,143 | $613,708 | $201,201 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 717 | 1,380 | $271,724 | $88,879 | 32.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 216 | 216 | $112,022 | $35,266 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 153 | 204 | $80,450 | $27,610 | 34.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 323 | 1,066 | $36,326 | $8,177 | 22.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 84 | 91 | $11,217 | $3,499 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 30 | 30 | $11,873 | $3,495 | 29.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2022 | 15 | 15 | $6,366 | $1,820 | 28.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $3,845 | $1,115 | 29.0% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 12 | 12 | $1,914 | $785.70 | 41.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 13 | 13 | $605.34 | $228.59 | 37.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 762 | 2,031 | $487,409 | $183,343 | 37.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 892 | 1,599 | $255,840 | $100,954 | 39.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 201 | 201 | $91,455 | $31,681 | 34.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 163 | 198 | $63,228 | $25,381 | 40.1% |
About Dr. Gary Thomas, MD
Dr. Gary Thomas, MD is a Hematology & Oncology healthcare provider based in Hilton Head Island, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1043218316.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Thomas, MD has received a total of $63,874 in payments from pharmaceutical and medical device companies, with $11,797 received in 2024. These payments were reported across 715 transactions from 74 companies. The most common payment nature is "Consulting Fee" ($36,393).
As a Medicare-enrolled provider, Thomas has provided services to 10,461 Medicare beneficiaries, totaling 22,674 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Hilton Head Island, SC
- Active Since 07/12/2005
- Last Updated 06/16/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1043218316
Products in Payments
- Pomalyst (Drug) $8,508
- Zydelig (Drug) $5,210
- MONOFERRIC (Drug) $4,142
- BRUKINSA (Drug) $3,220
- SCEMBLIX (Drug) $2,480
- Lenvima (Drug) $2,340
- LYNPARZA (Drug) $2,175
- Vitrakvi (Drug) $2,025
- Rituxan (Drug) $1,800
- Tecartus (Drug) $1,700
- KEYTRUDA (Biological) $1,429
- PADCEV (Biological) $1,370
- Stivarga (Drug) $1,138
- OPDIVO (Biological) $1,127
- Venclexta (Drug) $1,026
- CALQUENCE (Drug) $779.86
- TAGRISSO (Drug) $506.17
- NINLARO (Drug) $452.70
- JAKAFI (Drug) $346.26
- REBLOZYL (Biological) $345.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.